Skip to content
CNS Clinical Research

Orange, California

CNS clinical trials in Orange, CA

44 CNS studies are recruiting participants at sites in Orange as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.

Call (888) 520-7418
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Orange at a glance

  • 44 studies are recruiting at a site in Orange.
  • By phase: Phase 1/2 (2), Phase 2 (12), Phase 3 (22), Phase 4 (3), No phase (1), Observational (4). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (37), university, hospital or other (7).
  • By research area: Depression (18), Epilepsy (9), Schizophrenia (6), Bipolar Disorder (3), Parkinson's Disease (3), ADHD (2), Multiple Sclerosis (2), Migraine (1).
  • Most recent update to one of these records: November 16, 2026.

Depression studies recruiting in Orange

Basic details from each study's public record (the 30 most recently updated of 44). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study sites
    ATP Clinical Research · NRC Research Institute
    Registry record
    NCT07226661 · updated
  2. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 85
    • All sexes
    Sponsor
    Cybin IRL Limited
    Study sites
    ATP Clinical Research · NRC Research Institute
    Registry record
    NCT06793397 · updated
  3. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Definium Therapeutics US, Inc.
    Study site
    ATP Clinical Research Orange County
    Registry record
    NCT07592689 · updated
  4. ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    ACADIA Pharmaceuticals Inc.
    Study site
    PNS Clinical Research LLC dba ATP Clinical Research
    Registry record
    NCT07284667 · updated
  5. E-Mindfulness Approaches for Living After Breast Cancer

    • Phase 3
    • Ages 18 to 50
    • All sexes
    Sponsor
    NRG Oncology
    Study site
    UC Irvine Health/Chao Family Comprehensive Cancer Center
    Registry record
    NCT06748222 · updated
  6. A Study of Brenipatide in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    ATP Clinical Research
    Registry record
    NCT07412756 · updated
  7. TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age

    • Observational
    • From 18 months, up to 11 years
    • All sexes
    Sponsor
    State University of New York at Buffalo
    Study site
    Children's Hospital of Orange County
    Registry record
    NCT07048574 · updated
  8. A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    NRC Research Institute
    Registry record
    NCT07573176 · updated
  9. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT06966401 · updated
  10. A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Tonix Pharmaceuticals, Inc.
    Registry record
    NCT07621237 · updated
  11. A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT07196501 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Orange, CA on ClinicalTrials.gov.

Schizophrenia studies recruiting in Orange

  1. A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

    • Phase 2
    • Ages 55 to 90
    • All sexes
    Sponsor
    MapLight Therapeutics
    Registry record
    NCT06887192 · updated
  2. A Study to Evaluate the Effect of KarXT on Urological Safety

    • Phase 4
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    ATP Clinical Research
    Registry record
    NCT07221877 · updated
  3. Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    NRC Research Institute
    Registry record
    NCT07686263 · updated
  4. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    MapLight Therapeutics
    Registry record
    NCT07459647 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Orange, CA on ClinicalTrials.gov.

Bipolar disorder studies recruiting in Orange

  1. A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    ATP Clinical Research
    Registry record
    NCT07286175 · updated
  2. A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    NRC Research Institute
    Registry record
    NCT07140913 · updated
  3. A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    NRC Research Institute
    Registry record
    NCT06929273 · updated

Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Orange, CA on ClinicalTrials.gov.

ADHD studies recruiting in Orange

  1. The Myelin Disorders Biorepository Project

    • Observational
    • All ages
    • All sexes
    Sponsor
    Children's Hospital of Philadelphia
    Study site
    Children's Hospital of Orange County
    Registry record
    NCT03047369 · updated
  2. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

    • Phase 3
    • Ages 6 to 11
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717879 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Orange, CA on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Orange

  1. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 6020)
    Registry record
    NCT06952504 · updated
  2. A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of California Irvine Medical Center ( Site 6006)
    Registry record
    NCT07216703 · updated
  3. A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

    • Phase 3
    • Ages 45 to 75
    • All sexes
    Sponsor
    BlueRock Therapeutics
    Study site
    UCI Medical Center - Neurology
    Registry record
    NCT06944522 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Orange, CA on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Orange

  1. A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT06433752 · updated
  2. Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT05877963 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Orange, CA on ClinicalTrials.gov.

Epilepsy studies recruiting in Orange

  1. A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    University of California, Irvine - Health Neurology Services
    Registry record
    NCT05667142 · updated
  2. A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    University of California Irvine Health
    Registry record
    NCT05716100 · updated
  3. Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Neurona Therapeutics
    Study site
    UC Irvine Medical Center
    Registry record
    NCT05135091 · updated
  4. A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

    • Phase 3
    • Ages 2 and older
    • All sexes
    Sponsor
    Epygenix
    Study site
    University of California Irvine
    Registry record
    NCT04462770 · updated
  5. A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy

    • Phase 1/2
    • Ages 2 to 12
    • All sexes
    Sponsor
    Institut de Recherches Internationales Servier
    Study site
    Children's Hospital of Orange County
    Registry record
    NCT07227857 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Orange, CA on ClinicalTrials.gov.

Ask about studies near Orange

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in California

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 520-7418

or send a short form

How should we reach you?

Call